JP7118884B2 - Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物 - Google Patents

Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物 Download PDF

Info

Publication number
JP7118884B2
JP7118884B2 JP2018502129A JP2018502129A JP7118884B2 JP 7118884 B2 JP7118884 B2 JP 7118884B2 JP 2018502129 A JP2018502129 A JP 2018502129A JP 2018502129 A JP2018502129 A JP 2018502129A JP 7118884 B2 JP7118884 B2 JP 7118884B2
Authority
JP
Japan
Prior art keywords
cells
ppi
disease
antigen
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018502129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522011A5 (enExample
JP2018522011A (ja
Inventor
マローネ，ロベルト
キュリーナ，スロボダン
ギュプタ，ニメシュ
ラクロワ－デスマゼス，セバスチャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorbonne Universite
Universite Paris Cite
Original Assignee
Sorbonne Universite
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorbonne Universite, Universite Paris Cite filed Critical Sorbonne Universite
Publication of JP2018522011A publication Critical patent/JP2018522011A/ja
Publication of JP2018522011A5 publication Critical patent/JP2018522011A5/ja
Priority to JP2022107727A priority Critical patent/JP7578646B2/ja
Application granted granted Critical
Publication of JP7118884B2 publication Critical patent/JP7118884B2/ja
Priority to JP2024187654A priority patent/JP2025020198A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2018502129A 2015-07-17 2016-07-13 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物 Active JP7118884B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022107727A JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2024187654A JP2025020198A (ja) 2015-07-17 2024-10-24 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306169 2015-07-17
EP15306169.2 2015-07-17
PCT/EP2016/066690 WO2017012959A1 (en) 2015-07-17 2016-07-13 Methods and pharmaceutical compositions for inducing immune tolerance by mucosal vaccination with fc-coupled antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022107727A Division JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Publications (3)

Publication Number Publication Date
JP2018522011A JP2018522011A (ja) 2018-08-09
JP2018522011A5 JP2018522011A5 (enExample) 2019-08-15
JP7118884B2 true JP7118884B2 (ja) 2022-08-16

Family

ID=53776517

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018502129A Active JP7118884B2 (ja) 2015-07-17 2016-07-13 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2022107727A Active JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2024187654A Pending JP2025020198A (ja) 2015-07-17 2024-10-24 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022107727A Active JP7578646B2 (ja) 2015-07-17 2022-07-04 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
JP2024187654A Pending JP2025020198A (ja) 2015-07-17 2024-10-24 Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物

Country Status (4)

Country Link
US (3) US10507234B2 (enExample)
EP (1) EP3325004A1 (enExample)
JP (3) JP7118884B2 (enExample)
WO (1) WO2017012959A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6554473B2 (ja) 2013-12-24 2019-07-31 アルゲン−エックス ビーブイビーエー ＦｃＲｎアンタゴニスト及び使用方法
KR20200096786A (ko) * 2017-12-08 2020-08-13 아르제넥스 비브이비에이 전신 중증 근무력증의 치료를 위한 FcRn 길항제의 용도
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
CA3163172A1 (en) 2020-01-08 2021-07-15 Peter Verheesen Methods for treating pemphigus disorders
CN119630697A (zh) 2022-06-15 2025-03-14 阿根思有限公司 Ph依赖性hsa结合分子及使用方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066095A2 (en) 2002-02-07 2003-08-14 Vereniging Voor Christelijk Wetenschappelijk Onderwijs MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING
JP2008007513A (ja) 1995-01-17 2008-01-17 Brigham & Women's Hospital Inc 免疫原の受容体特異的経上皮輸送
JP2010523132A (ja) 2007-04-11 2010-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブカリフォルニア Ｉｇ−ｐＣｏｎｓｅｎｓｕｓ遺伝子ワクチン接種は、自己免疫疾患における抗体依存性の免疫病態から保護する
US20120213780A1 (en) 2011-02-23 2012-08-23 Xiaoping Zhu Efficient mucosal vaccination mediated by the neonatal Fc receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US9517257B2 (en) * 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US20170072032A1 (en) * 2015-07-02 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Prenatal therapy to induce immune tolerance

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008007513A (ja) 1995-01-17 2008-01-17 Brigham & Women's Hospital Inc 免疫原の受容体特異的経上皮輸送
WO2003066095A2 (en) 2002-02-07 2003-08-14 Vereniging Voor Christelijk Wetenschappelijk Onderwijs MODULATING TOLERANCE BY MODULATING FcϜRIIB RECEPTOR SIGNALLING
JP2010523132A (ja) 2007-04-11 2010-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブカリフォルニア Ｉｇ−ｐＣｏｎｓｅｎｓｕｓ遺伝子ワクチン接種は、自己免疫疾患における抗体依存性の免疫病態から保護する
US20120213780A1 (en) 2011-02-23 2012-08-23 Xiaoping Zhu Efficient mucosal vaccination mediated by the neonatal Fc receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Diabetes，2015年04月，Vol.64，pp.3532-3542

Also Published As

Publication number Publication date
JP2022130681A (ja) 2022-09-06
US20200155658A1 (en) 2020-05-21
US20220175896A1 (en) 2022-06-09
EP3325004A1 (en) 2018-05-30
US10507234B2 (en) 2019-12-17
JP2018522011A (ja) 2018-08-09
WO2017012959A1 (en) 2017-01-26
JP2025020198A (ja) 2025-02-12
JP7578646B2 (ja) 2024-11-06
US20180207250A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
JP7578646B2 (ja) Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
CN106573966B (zh) 用于治疗代谢异常的组合物和方法
AU744885B2 (en) Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
EP1292621B1 (en) Compositions for treating autoimmune disease
US20170304432A1 (en) Nucleic acids for treatment of peanut allergies
US20160060358A1 (en) Induction of antigen-specific tolerance
JP4857396B1 (ja) 融合蛋白質
US20090280132A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
JP2021504488A (ja) 自己免疫性疾患を治療する方法
US20070218053A1 (en) Coupling of peripheral tolerance to endogenous il-10 promotes effective modulation of t cells and ameliorates autoimmune disease
TW202015753A (zh) 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
US20210177967A1 (en) Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
JP2009532361A (ja) Ｉｇｅを標的としたｄｎａワクチン接種
US20170072032A1 (en) Prenatal therapy to induce immune tolerance
ES2615881T3 (es) Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
Clemente Casares pMHC-class II nanovaccine to treat autoimmune diseases
ES2301794T3 (es) Tratamiento de la diabetes de tipo 1, antes y despues de la expresion de marcadores de predisposicion.
WO2004004642A2 (en) TCELL TOLERANCE AND MODULATION OF AUTOIMMUNITY BY CD8α-CD4+ DENDRITIC CELLS
Baranyi et al. A chimerism-based approach to induce tolerance in IgE-mediated allergy
CN119137156A (zh) 用于免疫耐受的抗asgr1多肽和使用方法
JP2023542036A (ja) ＩｇＥ介在性炎症性障害を治療するためのＩｇＥフラグメントを含む免疫原性産物
CN120897758A (zh) Covid-19融合蛋白的核衣壳抗原免疫疗法和使用方法
Konrad et al. The dominant immune response to intestinal bacterial antigens is ignorance, rather than tolerance
Pfrengle et al. Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20210826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210827

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210827

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211119

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220803

R150 Certificate of patent or registration of utility model

Ref document number: 7118884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250